Fosun Kaiti Showcases Multiple Cell Therapy Data in B-cell Malignancies and Membranous Nephropathy at ASGCT 2026
Fosun Kairos
Developer of Tumor Immune Cell Therapy Technologies and Products
The 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT 2026) will be held in Boston, USA, from May 11 to 15, 2026. At this academic conference, Fosun Pharma's subsidiary, Fosun Kite Biotechnology Co., Ltd., and Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine will present the latest advancements in five key studies. Two innovative products from Fosun Kite’s pipeline, FKC118 (enhanced CD19/CD20 CAR-T) and FKC289 (BCMA/CD19 CAR-T manufactured using the innovative Fosunova-T platform), show "first-in-class" or "best-in-class" potential, focusing on cutting-edge treatment exploration in B-cell malignancies and membranous nephropathy. Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine further enhances the benefits of CD19 CAR-T cell therapy in patients with large B-cell lymphoma through research into TP53 mutations and bridging therapies.
Among them, Professor Liu Zhihong, an academician of the Chinese Academy of Engineering, is leading the FKC289 study in the field of membranous nephropathy (MN). Professor Zhao Weili, Vice President of Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine and Director of the Shanghai Institute of Hematology, is leading a total of four studies in the field of large B-cell lymphoma, further highlighting the innovative strength of Chinese experts.
FKC118 (Enhanced CD19/CD20 CAR-T)
FKC118 is an enhanced dual-target autologous CAR-T product targeting CD19 and CD20. The dual-target CAR structure design effectively reduces the risk of recurrence caused by antigen escape, while the innovative and optimized enhanced components further improve the expansion and persistence of T cells in vivo, alleviating the risk of recurrence due to reduced T cell function, thereby expecting to bring more durable and effective clinical benefits.
Abstract Title:Enhanced Dual-Target CD19/CD20 Chimeric Antigen Receptor T-Cell Therapy for B-Cell Malignancies
An enhanced dual-targeting CD19/CD20 chimeric antigen receptor T cell therapy for B-cell malignancies
Display Format:Poster
Poster Number：3253
Display Time:May 11-15, 2026
Principal Investigator:Hai-Hua Gu, Rui-Na He, Wei-Wei Zhang, Ping Tan, Li-Yuan Jin
FKC289（BCMA/CD19 CAR-T）
FKC289 is a dual-target autologous CAR-T product manufactured using the innovative Fosunova-T platform, targeting both BCMA and CD19. By simultaneously targeting surface antigens BCMA and CD19, it achieves deep depletion of pathogenic plasma cells and/or B cells, thereby treating plasma cell disorders and/or B cell-mediated autoimmune diseases. FKC289 is applicable in primary light chain amyloidosis (ALA),PrimaryMembranous Nephropathy (MN)and other diseases achieve deep and sustained remission, it is expected to become a more efficient and safer standardized solution.
Currently, FKC289 has received clinical trial approval from the National Medical Products Administration (NMPA) to conduct Phase I/II clinical studies for this product, respectively forRelapsed/Refractory Primary Membranous Nephropathy(R/R MN) and relapsed/refractory primary light chain amyloidosis (R/R ALA). Patient enrollment is ongoing.
Abstract Title:Membranous NephropathyEncountering Innovative Anti-CD19 and Anti-BCMA Dual-Target CAR-T Therapy: First-in-Human Clinical Trial Demonstrates Efficacy, Prepared Based on the Fosunova-T Innovation Platform
Membranous Nephropathy Meets a Novel Anti-CD19 & Anti-BCMA Dual CAR-T Therapy that’s a First in Human Clinical Performance and Manufactured Using an Innovative Fosunova-T Platform
Display Format:Poster
Poster Number：2183
Display Time:May 11-15, 2026
Principal Investigator:Wen-Shi Wang, Xi-Lin Chen, Yong Yang, Jian Zhang, Li Hou, He Xin, Li-Shen Wang, Ai-Dong Shan, Wen Shi, Wen-Cui Chen, Jin-Zhou Guo, Xiao-Mei Wu, Xiang-Hua Huang, Zhi-Hong Liu
Abstract Title:BCMA-CD19 Dual-Target CAR-T Cell TherapyRecurrent and Refractory PLA2R-Associated Membranous NephropathySafety and Efficacy of (MN)
Efficacy and Safety of FKC289, a BCMACD19 dualtargeted CART therapy for refractory or relapsed PLA2R-associated Membranous Nephropathy
Display Format:Poster
Poster Number:2370
Display Time:May 11-15, 2026
Principal Investigator:Xiang-Hua Huang, Wen-Cui Chen, Wei-Wei Xu, Jin-Zhou Guo, Xiao-Mei Wu, Da-Chang Chen, Wen-Hao Chen, Ai-Dong Shan, Yong Yang, Wen-Shi Wang, Zi-Song Zhou, Yun L, Wen Shi, Zhi-Hong Liu
As the first CAR-T product approved in China, Axicabtagene Ciloleucel Injection has successfully benefited numerous R/R LBCL patients and continues to expand its clinical value. Driven by the Fosun Kite Medical team, the growing experience of clinical experts in using the commercial CD19 CAR-T product has led to the continuous generation of new research evidence.
At the ASGCT 2026 conference, exploratory results from Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, on cell therapy for TP53 mutations and bridging treatment made a significant debut.
Abstract Title:The Impact of TP53 Gene Mutation on CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma
Impact of TP53 mutation on CD19-Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma
Display Format:Poster
Poster Number：1374
Display Time:May 11-15, 2026
Principal Investigator:Ling-Shuang Sheng, Rong Shen, Zi-Xun Yan, Jing-Hua Zhao, Wei-Li Zhao, Li Wang
Abstract Title:Tumor Burden-Adaptive Bridging Therapy Improves CD19 CAR-T Treatment Outcomes in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Phase II, Single-Center Prospective Study
Tumor Burden-Adapted Bridging Therapy Improves CD19 CAR-T Outcomes in Relapsed or Refractory Large B-cell Lymphoma: A Phase II, Single-Center Prospective Study
Display Format:Poster
Poster Number：3375
Display Time:May 11-15, 2026
Principal Investigator:Zi-Xun Yan, Niu Qiao, Shu-Bei Wang, Ling-Shuang Sheng, Rong Shen, Ting-Ting Pan, Qi Song, Xu-Feng Jiang, Hong-Mei Yi, Wen Wu, Li Wang, Shu Cheng, Peng-Peng Xu, Jing-Hua Zhao, Wei-Li Zhao
Fosun Kite is accelerating the expansion of cell therapy into more disease areas. With the continuous accumulation and transformation of key clinical data, the company is expected to secure a more certain long-term position in the global cell therapy competition.
